Direct-to-consumer marketing limits and how they differ by market

In 1998 Pfizer put Bob Dole on American television to talk about erectile dysfunction. The spot never named Viagra. Within a couple of years branded Viagra advertising was running too, and both formats still exist side by side. The gap between them is the mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition → this lesson draws: in the United States and New Zealand you may say the product name to a patient, and almost everywhere else the Dole version is the only campaign you are allowed to make.

That is not a translation problem. It forks the brand plan: different assets, different conversion metrics, different media buys, and in a few markets a regulator who reads the file before you spend anything.

Two permissive markets, and what permissive means

The United States and New Zealand are the only two countries that allow branded advertising of prescription medicines to the general public in broadcast media. US practice traces to FDA guidance in the late 1990s that set out how a broadcast ad could satisfy "adequate provision" for risk information without reciting the full prescribing information on air. That clarification created the modern TV spot, and with it a US direct-to-consumer spend in the order of six billion dollars a year and up, most of it television.

New Zealand's permission sits in the Medicines Act 1981 and is administered by Medsafe, and it looks different in practice. Prescription medicine ads there carry mandatory statements sending the patient to a doctor, plus a statement of the principal risks, and advertisers routinely put material through the industry pre-vetting service before it runs. Successive New Zealand governments have reviewed a ban and none has enacted one.

Two structural facts global teams underweight. New Zealand's population is around five million, so it almost never justifies a bespoke branded campaign on its own economics; the legal permission is real and commercially marginal. And Australia, next door, prohibits prescription medicine advertising to the public, which makes trans-Tasman spillover (shared broadcast feeds, shared search inventory, shared influencer audiences) an exposure rather than a hypothetical.

What the US version has to carry, and what it does not

Benefit claims in a US consumer ad trigger the risk-disclosure obligations the patient-facing lesson in this module sets out; assume those apply and read on for the jurisdictional plumbing.

There is no general pre-clearance. A company can air a spot without FDA sign-off, and the agency reacts afterwards through untitled or warning letters (the database of OPDP enforcement letters is the public record). The exception worth knowing: products approved under accelerated approval must submit promotional material to FDA roughly a month before first use, so a single regulatory pathway can quietly turn a permissive market into a pre-vetted one.

Two formats sit below the full branded ad and both matter for global adaptation:

• Reminder ads: brand name, dosage form, no indication and no efficacy claim, and therefore no risk statement. They are unavailable for products carrying a boxed warning, which is precisely when a team most wants them.
• Help-seeking ads: the condition, the symptoms, "see your doctor", no product. This is the same creative territory the EU permits, which is why one production can feed both regions.

The trap is running the two together. Reminder and help-seeking material in the same market, same media slot, same visual signature, reads as one branded advertisement, and the promotional-content lesson in this module explains the tests a regulator applies to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → that conclusion.

An edge case that shows where the US rulebook stops: Hims & Hers, a telehealth company that sells the prescription products it advertises, ran a Super Bowl spot in February 2025 built around weight loss. The criticism it drew arrived as letters from senators to FDA rather than as an OPDP action, because the promotion sat around a compounded product rather than an approved branded drug with a sponsor obligated by DTC ad rules. Platform advertisers are reshaping who does the advertising, and the geography of the rules has not caught up.

What everyone else allows instead

Article 88(1) of Directive 2001/83/EC bans advertising prescription-only medicines to the general public across the EU. The substitute is unbranded disease awareness work: prevalence, symptoms, burden, a prompt to talk to a physician, no product name and no claim that ties a named medicine to the condition.

Three details change how you plan:

• The European Medicines Agency approves the Summary of Product Characteristics, which is the claim ceiling, but it does not police consumer advertising. Enforcement is national, and interpretation varies by member state, so one EU-wide asset can pass in one country and be challenged in another.
• Vaccination campaigns are carved out of the ban under the same directive when the competent national authority approves them, which is why public vaccination messaging can look far more branded than anything else you are permitted to run.
• Canada offers a third model rather than a binary: reminder ads limited to name, price and quantity, or help-seeking ads with no product. Each is legally half of a US ad, and joining them is the violation.

Forking one campaign: what actually changes

Separate the emotional concept from the claim architecture. Only the second one gets rebuilt.

1. Keep: hook, tone, casting, patient personapersonaA semi-fictional, research-based representation of your ideal customer: their goals, frustrations, behaviours and decision criteria.View full definition →. These travel.
2. Strip for non-permissive markets: brand name, drug class where it identifies the product, efficacy figures, any call to actioncall to actionA button, link, or message that prompts users to take a specific action such as sign up, buy, download, or learn more.View full definition → naming the treatment.
3. Rebuild: disease education plus a route to a clinician or an unbranded site. Branded promotion to healthcare professionals stays available in the EU under separate rules, so the branded weight moves channel rather than disappearing.
4. Re-verify substantiation against the document that governs that market: the FDA-approved label in the US, the SmPC in the EU. An indication approved in one is not automatically approved in the other, and campaigns have to be built on the narrower of the two where assets are shared.
5. GeoGeoThe practice of making your brand and content visible and citable inside AI-generated answers from tools like ChatGPT, Gemini and Perplexity.View full definition →-gate everything digital. A branded US site, a US paid social post or a US influencer audience that reaches German or French users is an EU exposure. Country selectors and interstitials exist for a reason, and paid targeting settings need the same discipline.

Budget consequence teams underestimate: the permissive markets get a measurable funnelfunnelThe customer journey from awareness to purchase, typically Awareness, Interest, Consideration, Decision, Action, with prospects narrowing at each stage.View full definition → (branded search, site visits, discussion-with-doctor surveys), while the unbranded markets get awareness metrics with no attributable path to a prescription. If the same global KPIKPIKey Performance Indicator, a measurable value that shows how effectively you're achieving a specific objective, tracked over time against a target.View full definition → set is applied to both, the EU campaign will look like it failed.

Off-label promotion: the shared floor

Neither regime lets you promote outside the approved indication, population or dose in that market. The subtle version, and the one unbranded work runs into, is a disease awareness campaign that educates about a group your product is not approved to treat: paediatric patients, or a milder disease severity. No brand name appears, and it is still promotion of an unapproved use if your product is the only realistic answer to the awareness you created.

Enforcement asymmetry drives where the money risk sits. In the US, False Claims Act liability with whistleblower relators has produced pharma settlements in the billions. The EU has no equivalent private-relator mechanism; exposure there runs through national agencies, self-regulatory rulings and reputational damage, which changes what a country manager will actually fear.

Pre-clearance: who reads it before you air

The internal gate, asset routing and medical, legal and regulatory sign-off is the subject of the pre-launch lesson in this module. What varies by geography is who outside the company gets a look first:

• United States: nobody, for most products, with the accelerated approval submission window as the exception.
• New Zealand: industry pre-vetting in practice before broadcast, on top of Medsafe's requirements.
• France: the national agency issues a visa for medicine advertising, so public-facing material is authorised before it runs, not judged afterwards.
• Elsewhere in the EU: mostly complaint-driven review by national agencies and self-regulatory bodies, often triggered by a competitor rather than a regulator.

Sequencing follows from that list. In a pre-vetting market you build lead time into the launch calendar; in the US you build reserve into the media plan, because an ad can be pulled after it has aired and the production cost is already sunk. For FDA's own primer on how it looks at consumer drug advertising, the Basics of Drug Ads page is a clean free reference.

🎬 [VIDEO: "How Pharma Advertising Works (and Why It's Banned in Most Countries)" - youtube.com - search this title on YouTube for an accessible explainer comparing US DTC ad rules to global restrictions, useful as a visual companion to this lesson]

Key takeaways

• Only the US and New Zealand permit branded prescription DTC in broadcast; the EU bans it under Article 88(1) of Directive 2001/83/EC, with a carve-out for approved vaccination campaigns, and Canada sits in between with reminder ads and help-seeking ads that may not be combined.
• New Zealand's permission is legally real and commercially small, and Australia's ban next door makes media spillover the practical risk of using it.
• The portable part of a global campaign is the concept; the claim architecture is rebuilt against the approved label or the SmPC of each market, and digital assets need geo-gating because an EU viewer of a US branded page is an EU problem.
• The European Medicines Agency sets the claim ceiling through the SmPC but does not enforce advertising, so a single EU asset can survive one member state and be challenged in another.
• Who checks before you air is jurisdiction-specific: no general US pre-clearance, pre-vetting in New Zealand, a national visa in France, and complaint-driven review across much of the EU, which changes launch lead times and how much media budget you keep in reserve.